Livforsakringsbolaget Skandia, Omsesidigt Bei Gene, Ltd. Put Options Transaction History
Livforsakringsbolaget Skandia, Omsesidigt
- $1.85 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding BGNE
# of Institutions
252Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.4 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.46 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.17 Billion26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$1.13 Billion0.84% of portfolio
-
Baillie Gifford & CO3.67MShares$832 Million0.54% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...